🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Metastatic Biliary Tract Carcinoma

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors NCT05733000Phase 21 site📍 Chicago Northwestern University · Tests: Biospecimen Collection, Computed Tomography, Devimistat, Fluorouracil, Gemcitabine Hydrochloride Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma NCT07780838Phase 21 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Biospecimen Collection, Cisplatin, Computed Tomography, Durvalumab, Gemcitabine Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer NCT07392541Phase 1, Phase 21 site📍 Wuhan Tongji Hospital · Tests: Adebrelimab, Gemcitabine + Cisplatin, Simvastatin 20mg Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors NCT07277413Phase 123 sites📍 Goodyear📍 Phoenix📍 Duarte IDEAYA Biosciences · Tests: IDE892, IDE397 A Phase 1 Study of LNCB74 in Advanced Solid Tumors NCT06774963Phase 114 sites📍 Newport Beach📍 Edgewood📍 Boston NextCure, Inc. · Tests: LNCB74 BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion NCT07594626Phase 1, Phase 21 site📍 Chicago Northwestern University · Tests: Biospecimen Collection, Computed Tomography, Pemetrexed, PRMT5 Inhibitor BMS-986504 A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer NCT07450976Phase 22 sites📍 Beijing📍 Shanghai Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-A1904 for Injection Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer NCT07670273Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Trastuzumab Rezetecan, Adebrelimab, Lenvatinib A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors NCT06043466Phase 12 sites📍 Hangzhou📍 Hangzhou Chongqing Precision Biotech Co., Ltd · Tests: CEA-targeted CAR-T cells Determination of Copper and Other Trace Elements in Serum Samples From Patients With Biliary Tract Cancers NCT06060990NA1 site📍 Ljubljana Institute of Oncology Ljubljana · Tests: trace elements A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites📍 Sacramento📍 Celebration📍 Miami Marengo Therapeutics, Inc. · Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio NCT05655949Phase 21 site📍 Boston Beth Israel Deaconess Medical Center · Tests: Gemcitabine, Cisplatin, Durvalumab, Yttrium-90 PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma NCT05286814Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP), Floxuridine Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors NCT04900818Phase 121 sites📍 Orange📍 Aurora📍 Layfayette I-Mab Biopharma US Limited · Tests: TJ033721 (givastomig), TJ033721 (givastomig) , nivolumab, chemotherapy, TJ033721 (givastomig), chemotherapy, TJ033721 (… Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors NCT06975410Phase 1, Phase 24 sites📍 Seoul📍 Seoul📍 Seoul Yuhan Corporation · Tests: YH32364 A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer NCT06778031Phase 22 sites📍 Harbin📍 Shanghai Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Tests: SHR-A1811, SHR-1316, SHR-8068 CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors NCT06937567EARLY Phase 11 site📍 Hangzhou Zhejiang University · Tests: CDH17 CAR-T, FAST LACO-Stim CDH17 CAR-T A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies NCT07197554Phase 16 sites📍 Duarte📍 Newport Beach📍 Boston SEED Therapeutics, Inc. · Tests: ST-01156 Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer NCT07831993Phase 21 site📍 Nanjing The Affiliated Nanjing Drum Tower Hospital of Nanjing Unive… · Tests: Sintilimab, Irinotecan Hydrochloride Liposome Injection (II), Oxaliplatin, Leucovorin, Fluorouracil A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer NCT06431490Phase 1, Phase 243 sites📍 Fuyang📍 Hefei📍 Hefei Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Phar… · Tests: TQB2102 for injection The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750Phase 1, Phase 276 sites📍 Irvine📍 La Jolla📍 Los Angeles PMV Pharmaceuticals, Inc · Tests: rezatapopt, pembrolizumab CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers NCT06548412Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Gemcitabine, Cisplatin, Durvalumab, CTX-009 Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer NCT07107750Phase 11 site📍 St Louis Washington University School of Medicine · Tests: Emavusertib, Gemcitabine, Cisplatin, Durvalumab This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors NCT06451497Phase 13 sites📍 Boston📍 Austin, TX 78758📍 San Antonio Zumutor Biologics Inc. · Tests: ZM008 A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation NCT07458347Phase 19 sites📍 Los Angeles📍 Sarasota📍 Tampa Kestrel Therapeutics, Inc. · Tests: KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab, Pembrolizumab, mFOLFOX6 Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients NCT07062263Phase 36 sites📍 Muzaffarpur📍 Mumbai📍 Bhubaneswar Tata Memorial Centre · Tests: Trastuzumab, Chemotherapy Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer NCT05705492Phase 21 site📍 Portland OHSU Knight Cancer Institute · Tests: Olanzapine, Placebo Administration, Questionnaire Administration A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure NCT07606599Phase 32 sites📍 Hefei📍 Beijing Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1, Oxaliplatin, Calcium levofolinate, Fluorouracil, Irinotecan Hydrochloride Liposome A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors NCT06270706Phase 122 sites📍 New Haven📍 Atlanta📍 Grand Rapids Pliant Therapeutics, Inc. · Tests: PLN-101095, PLN-101095, PLN-101095, PLN-101095, PLN-101095
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy